There are 398 resources available
173P - Entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer: updated data from STARTRK-2
Presenter: Janice Lu
Session: Poster Display session
174P - Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real world setting: Phase 3b LUCY final analysis
Presenter: Suzette Delaloge
Session: Poster Display session
175P - Alpelisib (ALP) + Endocrine Therapy (ET) in Patients (pts) With PIK3CA-Mutated, Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Advanced Breast Cancer (ABC): Subgroup Analyses From the BYLieve Study
Presenter: Fatima Cardoso
Session: Poster Display session
176P - Poziotinib for HER2-positive metastatic breast cancer (MBC): Final clinical efficacy and safety results for long-term follow-up of the phase II NOV120101-203 trial
Presenter: Yeon Hee Park
Session: Poster Display session
177P - Low HER2 expression does not influence prognosis in metastatic triple-negative breast cancer: results from an international, multicenter analysis coordinated by the Austrian Group Medical Tumor Therapy (AGMT)
Presenter: Simon Peter Gampenrieder
Session: Poster Display session
178P - Assessment of side effects (SEs) impacting quality of life (QoL) in patients (pts) undergoing treatment (tx) for advanced breast cancer (ABC) in clinical practice: a real-world (RW) multi-country survey
Presenter: Fatima Cardoso
Session: Poster Display session
179P - Time trends in overall survival and systemic therapy in patients with HR+/HER2- advanced breast cancer: a study of the SONABRE Registry
Presenter: Marissa Meegdes
Session: Poster Display session
180P - A doubling in overall survival of patients with de novo HER2+ advanced breast cancer in the Netherlands
Presenter: Sandra Geurts
Session: Poster Display session
181P - Efficacy of eribulin mesylate in HER2-low metastatic breast cancer (MBC): Results from a pooled analysis of two phase 3 studies
Presenter: Christopher Twelves
Session: Poster Display session
182P - Radium-223 (223Ra) in Combination with Exemestane and Everolimus (EXE-EVE) in Patients (pts) with Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative (HR+/HER2-) Metastatic Breast Cancer (MBC) with Bone Metastases: A Phase 2 Study
Presenter: Hope Rugo
Session: Poster Display session